{"id":4194,"date":"2017-01-04T11:05:01","date_gmt":"2017-01-04T16:05:01","guid":{"rendered":"http:\/\/blogs.shu.edu\/cancer\/?p=4194"},"modified":"2021-07-02T08:51:43","modified_gmt":"2021-07-02T12:51:43","slug":"bms-and-psooxus-collaborate-on-transgenic-oncolytic-virus-plus-nivolumab","status":"publish","type":"post","link":"http:\/\/blogs.shu.edu\/cancer\/2017\/01\/04\/bms-and-psooxus-collaborate-on-transgenic-oncolytic-virus-plus-nivolumab\/","title":{"rendered":"BMS and PsoOxus collaborate on transgenic oncolytic virus plus nivolumab"},"content":{"rendered":"

BMS paid PsiOxus $50MM upfront for exclusive rights<\/a> to develop\u00a0PsiOxus\u2019 NG-348 enadenotucirev<\/a>, a systemically administered oncolytic adenovirus therapeutic, in combination with Bristol-Myers Squibb\u2019s Immuno-Oncology checkpoint inhibitor\u00a0Opdivo<\/em><\/a>\u00a0(nivolumab) to treat a range of solid tumor types in late-stage cancer patients. This is a \u201cbig deal\u201d – \u00a0PsiOxus could receive up to $886 million in development, regulatory, and sales-based milestones, plus sales royalties.<\/p>\n

We previously discussed another combination of an engineered virus combined with a checkpoint inhibitor \u2013 see DNAtrix and Merck Phase II Collaboration of Oncolytic Virus + Keytruda for Glioblastoma<\/a>.<\/p>\n

What is enadenotucirev (ColoAd1)?<\/em><\/strong><\/p>\n

The NG-348 virus uses PsiOxus\u2019 proprietary Tumor-Specific Immuno-gene Therapy (T-SIGn)<\/a> platform to \u201carm\u201d adenovirus with two additional immuno-therapeutic transgenes: (1) full-length human CD80 and (2) a membrane-anchored antibody fragment specific for the T-cell receptor CD3 protein. The expression of these genes is controlled by endogenous virus major late promotor, which only allows expression of the proteins on the surface of virus-infected tumor cells, and prevents off-target expression in healthy cells.<\/p>\n

The virus (ColoAd1) was selected through a process of natural selection<\/a> from a large randomly-created adenovirus chimeric library. The viruses were tested against normal cells and cancer cells \u2013 selection was based on oncolytic potency against cancer cells potential to infect normal cells. Step one was directed selection for cancer cell killing; step two was screening against normal cells. ColoAd1 is 1200 times more potent in killing cancer cells than non-cancer cells. Following intravenous administration, because it is a large particle, it does not permeate normal endothelium, rather, accumulates in tumors with leaky vasculature. It replicates in cancer cells and induces non-apoptotic cell death; shed viral particles infect other cancer cells. Necrolytic cell death liberates tumor antigens that can trigger a specific adaptive immune response.<\/p>\n

\"Figure<\/a>

Figure 1. Natural Selection process for identifying oncolytic viruses with the greatest therapeutic window. http:\/\/psioxus.com\/technology-products\/enadenotucirev\/<\/a><\/p><\/div>\n

What is the importance of CD80 and CD3 accessory molecules?<\/em><\/strong><\/p>\n

In addition to its direct oncolytic action, the virus also induces the expression of CD80 on the surface of infected cancer cells, thereby enhancing interaction with T-cells by binding with CD28, thereby activating T-cells. The CD3 binding motif that is expressed on the infected cancer cells enables the cancer cell to engage the T-cell receptor (TCR) and precipitate a more vigorous T-cell response by stimulating the accessory molecule.<\/p>\n

CD3 is a multimeric protein complex<\/em><\/a>, known historically as the T3 complex, and is composed of four distinct polypeptide chains; epsilon (\u03b5), gamma (\u03b3), delta (\u03b4) and\u00a0zeta (\u03b6), that assemble and function as three pairs of dimers (\u03b5\u03b3, \u03b5\u03b4, \u03b6\u03b6). The CD3 complex serves as a T cell co-receptor that associates noncovalently with the T cell receptor (TCR).<\/em><\/p>\n

\"Figure<\/a>

Figure 2. T-cell receptor and CD3 accessory molecule. The receptor for antigens on the T cell surface comprises eight proteins. (a) Two disulfide-bonded chains of the T cell receptor which form a heterodimer. These recognize peptides associated with MHC molecules. (b) Four chains, collectively termed CD3, that associate with the T cell receptor dimer and participate in its transport to the surface of the cell. The CD3 complex together with the zeta chains, which form a homodimer, transduce the signal after antigen has bound http:\/\/www.microbiologybook.org\/bowers\/mhc.htm<\/a><\/p><\/div>\n

What is the rationale for combining enadenotucirev and nivolumab?<\/em><\/strong><\/p>\n

Enadenotucirev induces direct oncolytic killing of cancer cells. It also precipitates specific immune responses by two mechanisms (Figure 3):<\/p>\n

    \n
  1. Spilling of tumor antigens by direct necrolytic cell killing \u2013 dendritic cells present the antigens to the immune system thereby inducing an adaptive immune response;<\/li>\n
  2. Engagement of T-cells via CD28 binding of CD80 and TCR via binding with and activating accessory molecule CD3.<\/li>\n<\/ol>\n
    \"Figure<\/a>

    Figure 3. T-cell activation by three signals. The first involves T-cell receptor (TCR) triggering by donor antigen on APCs (antigen presenting cells). The second signal or \u201ccostimulation signal\u201d is delivered when B7-1\/CD80 and B7-2\/CD86 on the surface of APCs engage CD28 on T-cells. These two signals activate three transduction pathways (the Nuclear Factor-\u03baB or Nf-\u03baB pathway, the mitogen-activated protein (MAP) kinase pathway and the calcium-calcineurin pathway) that result in the production of numerous factors, including interleukin-2 (IL-2), the \u03b1\u2013chain of its receptor, CD25, and the CD40 Ligand. CD40 is expressed on all APCs (including B cells) and its ligand (CD40L or CD154) is on activated CD4+ T-cells and on a subset of CD8+ T-cells and NK cells. Stimulation of CD40 on APC by CD40L triggers important signals for antibody production by B cells and strongly induces B7 and Major Histocompatibility Complex (MHC) expression on APCs. IL-2 binding to its receptor activates the mTOR (\u201ctarget of rapamycin\u201d) pathway \u2013 the third signal \u2013 resulting in T-cell clonal proliferation. https:\/\/openi.nlm.nih.gov\/detailedresult.php?img=PMC2721321_btt-1-203f1&req=4<\/a><\/p><\/div>\n

    Once the immune reaction is induced, the use of nivolumab blocks the abrogation of the immune response by interfering with PD-1\/PD-L1 interactions between antigen presenting cells (cancer cells and dendritic cells) and cytotoxic T-cells. This results in reactivation of the adaptive immune response (Figure 4).<\/p>\n

    \"Figure<\/a>

    Figure 4. INF-\u03baB indicates nuclear factor-Kappa B; IFNy, interferon gamma; IFNyR, interferon-gamma receptor; MHC, major histocompatibility complex. Adapted from Nourkeyhani H, George S. J Targeted Ther Cancer. 2014;3(5):46-50. www.targetedonc.com. – See more at: http:\/\/www.onclive.com\/publications\/oncology-live\/2015\/january-2015\/pd-1-pathway-blockade-may-shape-the-future-of-hodgkin-lymphoma-therapy#sthash.qcie9ouY.dpuf<\/a><\/p><\/div>\n","protected":false},"excerpt":{"rendered":"

    BMS paid PsiOxus $50MM upfront for exclusive rights to develop\u00a0PsiOxus\u2019 NG-348 enadenotucirev, a systemically administered oncolytic adenovirus therapeutic, in combination with Bristol-Myers Squibb\u2019s Immuno-Oncology checkpoint inhibitor\u00a0Opdivo\u00a0(nivolumab) to treat a range of solid tumor types in late-stage cancer patients. This is a \u201cbig deal\u201d – \u00a0PsiOxus could receive up to $886 million in development, regulatory, and […]<\/p>\n","protected":false},"author":2252,"featured_media":3979,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[28,6],"tags":[1048,183,1840,1843,1842,89,882,749,41,40,1841],"class_list":["post-4194","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-checkpoint-inhibitors","category-immunology-immunotherapy","tag-bms","tag-cd3","tag-cd80","tag-coload1","tag-enadenotucirev","tag-nivolumab","tag-oncolytic-virus","tag-opdivo","tag-pd-1","tag-pd-l1","tag-psioxus"],"post_mailing_queue_ids":[],"_links":{"self":[{"href":"http:\/\/blogs.shu.edu\/cancer\/wp-json\/wp\/v2\/posts\/4194","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/blogs.shu.edu\/cancer\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/blogs.shu.edu\/cancer\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/blogs.shu.edu\/cancer\/wp-json\/wp\/v2\/users\/2252"}],"replies":[{"embeddable":true,"href":"http:\/\/blogs.shu.edu\/cancer\/wp-json\/wp\/v2\/comments?post=4194"}],"version-history":[{"count":4,"href":"http:\/\/blogs.shu.edu\/cancer\/wp-json\/wp\/v2\/posts\/4194\/revisions"}],"predecessor-version":[{"id":4881,"href":"http:\/\/blogs.shu.edu\/cancer\/wp-json\/wp\/v2\/posts\/4194\/revisions\/4881"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/blogs.shu.edu\/cancer\/wp-json\/wp\/v2\/media\/3979"}],"wp:attachment":[{"href":"http:\/\/blogs.shu.edu\/cancer\/wp-json\/wp\/v2\/media?parent=4194"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/blogs.shu.edu\/cancer\/wp-json\/wp\/v2\/categories?post=4194"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/blogs.shu.edu\/cancer\/wp-json\/wp\/v2\/tags?post=4194"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}